April 2023 - Pharma Strategies | Zimbabwe | Zambia & beyond!

Phone: +263 (242) 741 308/9

Home
About Us
Our Work
News
Media
Links
Privacy Policy
Contact
Search
Menu Menu

Alcon 11/16/2023 : Alcon’s Third Quarter 2023 Earnings Conference Call

April 27, 2023/by Alcon Events

http://www.pharmastrategies.org/wp-content/uploads/2019/12/Pharma-Strategies-Website-Logo-300x138.png 0 0 Alcon Events http://www.pharmastrategies.org/wp-content/uploads/2019/12/Pharma-Strategies-Website-Logo-300x138.png Alcon Events2023-04-27 14:02:072023-04-27 14:02:0711/16/2023 : Alcon’s Third Quarter 2023 Earnings Conference Call

NEWS SOURCES

Alcon
Novartis News
Sandoz News

TAGS

Alcon Blood Pressure Cancer Novartis Osteoarthritis Read more about A cancer patient gets a new lease on life Read more about A partnership against epilepsy Read more about Belonging here: How Novartis helped me come out as a transgender woman Read more about Drug delivery, service delivery, and the future of cancer care Read more about Empowering the next generation of healthcare leaders Read more about FDA approves Novartis Cosentyx® as the first new biologic treatment option for hidradenitis suppurativa patients in nearly a decade Read more about Giving voice to people with a misunderstood disease Read more about Going upstream to improve heart health in Philadelphia Read more about How I found my true purpose at Novartis Read more about In Colombia, a researcher works against a devastating disease Read more about Innovation fueled by compassion Read more about Latest Novartis Kisqali® NATALEE analysis reinforces 25% reduction in risk of recurrence across broad population of patients with early breast cancer; supports regulatory submissions Read more about Les actionnaires de Novartis approuvent toutes les résolutions proposées par le Conseil d’administration lors de l’Assemblée générale ordinaire Read more about Mentoring matters: how we grow together at Novartis Read more about New Novartis Fabhalta® (iptacopan) data show clinically meaningful and statistically significant proteinuria reduction of 38.3% versus placebo for patients with IgA nephropathy (IgAN) Read more about Novartis, au premier trimestre: croissance à deux chiffres du chiffre d’affaires et expansion de la marge core; hausse des prévisions pour 2024 Read more about Novartis and Medicines for Malaria Venture announce positive efficacy and safety data for a novel treatment for babies Read more about Novartis at the J.P. Morgan Healthcare Conference 2024 Read more about Novartis data show potential of remibrutinib as an oral treatment for chronic spontaneous urticaria providing significant symptom improvement as early as Week 2 Read more about Novartis delivers double-digit sales growth and core margin expansion in Q1; FY 2024 guidance raised Read more about Novartis erzielt im ersten Quartal ein zweistelliges Umsatzwachstum und steigert die Kerngewinnmarge; Prognose für das Geschäftsjahr 2024 erhöht Read more about Novartis expands production of Pluvicto™ with addition of its largest and most advanced radioligand therapy manufacturing facility in Indianapolis Read more about Novartis Financial Results – Q1 2024 Read more about Novartis implements manufacturing adjustments for ribociclib to ensure alignment with latest regulatory standards in eBC by end of Q2 Read more about Novartis investigational iptacopan Phase III study demonstrates clinically meaningful and statistically significant proteinuria reduction in patients with C3 glomerulopathy (C3G) Read more about Novartis Kesimpta® six-year efficacy data show substantial benefits in recently diagnosed treatment- naïve people with relapsing multiple sclerosis Read more about Novartis Kisqali® NATALEE analysis reinforces consistent reduction in risk of recurrence across key subgroups of patients with early breast cancer Read more about Novartis Lutathera® significantly reduced risk of disease progression or death by 72% as first-line treatment for patients with advanced gastroenteropancreatic neuroendocrine tumors Read more about Novartis radioligand therapy Lutathera® FDA approved as first medicine specifically for pediatric patients with gastroenteropancreatic neuroendocrine tumors Read more about Novartis receives FDA approval for Fabhalta® (iptacopan), offering superior hemoglobin improvement in the absence of transfusions as the first oral monotherapy for adults with PNH Read more about Novartis shares strategy and growth update at J.P. Morgan Healthcare Conference 2024 Read more about Novartis showcases significant data updates from Kisqali®, iptacopan and Scemblix® at SABCS and ASH Read more about Novartis tender offer for MorphoSys AG commences Read more about Novartis upgrades mid-term sales growth guidance, showcases its differentiated innovative medicines strategy and robust pipeline at R&D Day Read more about Novartis Scemblix® shows superior major molecular response (MMR) rates vs. standard‐of‐care TKIs in Phase III trial for newly diagnosed patients with chronic myeloid leukemia Read more about Shoulder to shoulder Read more about Violence against innocent people runs counter to our work to improve human health Read more about Water project revives rural community in India Rheumatoid Arthritis Sandoz

MENU

Home
About Us
Our Work
News
Media
Links
Privacy Policy
Contact

Calendar

April 2023
M	T	W	T	F	S	S
					1	2
3	4	5	6	7	8	9
10	11	12	13	14	15	16
17	18	19	20	21	22	23
24	25	26	27	28	29	30

« Jan Jul »

Follow us on Facebook

ADDRESS – ZIMBABWE

Suite 204, Block 1
Long Cheng Plaza
Mutley Bend, Belvedere
Harare, Zimbabwe

ADDRESS – ZAMBIA

Plot 43504
Apex Chalala
Off Kasama Road
Lusaka Zambia

News

Novartis and Medicines for Malaria Venture announce positive efficacy and safety data for a novel treatment for babies <5 kg with malariaApril 24, 2024 - 6:34 am

© Copyright 2015-2021 - PharmaStrategies

Privacy Policy